Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O60890
UPID:
OPHN1_HUMAN
Alternative names:
-
Alternative UPACC:
O60890; B9EIP8; Q5JQ81; Q6PCC1; Q8WX47
Background:
Oligophrenin-1, encoded by the gene with accession number O60890, plays a pivotal role in neuronal activity. It stimulates GTP hydrolysis of Rho family members, influencing dendritic spine growth and synaptic function stabilization. It is essential for AMPA receptor stabilization at postsynaptic sites, synaptic vesicle endocytosis at presynaptic terminals, and protecting NR1D1 from degradation.
Therapeutic significance:
Oligophrenin-1's malfunction is linked to Intellectual developmental disorder, X-linked, syndromic, Billuart type, characterized by intellectual disability, cerebellar hypoplasia, and facial dysmorphism. Understanding its role could lead to novel therapeutic strategies for this disorder.